You are here

CC-486

Go or no go? A quiet month ahead for US approval verdicts

EP Vantage

Fri, 08/28/20 - 10:29 am

Bristol-Myers Squibb

FDA accepts for priority review Bristol Myers Squibb’s application for CC-486 for maintenance treatment of adults in remission with AML

Pharmaceutical Business Review

Mon, 05/4/20 - 10:36 am

Bristol-Meyers Squibb

acute myeloid leukemia

Following Strong Phase III Results, BMS Plans to Seek Approval for AML Candidate CC-486

BioSpace

Tue, 12/10/19 - 11:38 pm

Bristol-Myers Squibb

Roche and Celgene set for battle in acute myelogenous leukaemia

EP Vantage

Wed, 09/18/19 - 09:54 am

acute myeloid leukemia

Celgene's AML drug clears late-stage test

Endpoints

Mon, 09/16/19 - 09:17 am

acute myeloid leukemia

Celgene's phase 3 AML test chalks up a win

Fierce Biotech

Fri, 09/13/19 - 10:52 am

acute myeloid leukemia

clinical trials

First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH

Yahoo/BusinessWire

Sun, 12/8/13 - 12:07 pm

myelodysplastic syndromes